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Abstract
Head and neck cancers (HNC) are defined as malignant tumours located in the upper aerodigestive tract and represents 5% 
of oncologic cases in adults in Spain. More than 90% of these tumours have squamous histology. In an effort to incorporate 
evidence obtained since 2017 publication, the Spanish Society of Medical Oncology (SEOM) presents an update of the squa-
mous cell HNC diagnosis and treatment guideline. Most relevant diagnostic and therapeutic changes from the last guideline 
have been updated: introduction of sentinel node biopsy in early  oral/oropharyngeal cancer treated with surgery, concomitant 
radiotherapy with weekly cisplatin 40 mg/m2 in the adjuvant setting, new approaches for HPV-related oropharyngeal cancer 
and new treatments with immune-checkpoint inhibitors in recurrent/metastatic disease.
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Introduction
Squamous cell carcinomas of the head and neck (SCCHN) 
are defined as malignant tumors arising from mucosal sur-
faces located in the upper aerodigestive tract (paranasal 
sinuses, nasopharynx, oropharynx, hypopharynx, larynx, 
oral cavity, nostrils). In Spain, SCCHN represents 5% of all 
new cancer diagnoses in adults, being the sixth neoplasm 
(fifth in men), similar to the European median, and a mor-
tality rate of three points below compared to the European 
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median [1]. The most important risk factor in our region 
continues to be tobacco and alcohol use, but human pap-
illomavirus (HPV) infection is a key etiological factor in 
oropharyngeal cancer burden, which is rising worldwide 
[2]. Despite the majority patients with early-stage SCCHN 
can be cured with surgery or radiation, those with aggres-
sive disease and those with locally advanced stages, that 
represents two-thirds of new diagnosis, are more likely to 
recur (50% 5-year overall survival) [2]. A multidisciplinary 
team, bringing together all professionals who specialize in 
the diagnosis and treatment of these patients, will make 
the decision to establish the best sequence of individual-
ized treatment for each patient. Within what is known as 
SCCHN, each location has a clinical presentation, staging, 
prognosis and different therapeutic approach. As this is a 
general guide, the particularities of each subsite will not be 
dealt with in depth. Nasopharyngeal cancer with a different 
epidemiological, pathological and natural history will not be 
included in this guide.
Methodology
SEOM guidelines have been developed with the consensus 
of ten oncologists from the Spanish Group for the Treatment 
of Head and Neck Tumors (TTCC) and SEOM. To assign a 
level and quality of evidence and a grade of recommendation 
to the different statements of this treatment guideline, the 
Infectious Diseases Society of America-US Public Health 
Service Grading System for Ranking Recommendations in 
Clinical Guidelines was used (Table 1). The final text has 
been reviewed and approved by all authors.
Diagnosis and staging
It is essential to start the diagnostic process with a good 
clinical history, including toxic and sexual habits and a 
methodical physical examination, with special attention to 
the head and neck area (inspection, indirect mirror exami-
nation or direct endoscopy and palpation of primary sites 
and neck).
To explore tumor extension, diagnosis imaging is 
needed:
-Imaging diagnosis before a large biopsy avoids false 
diagnosis from anatomy distortion [2].
-Cervical computed tomography (CT) or magnetic reso-
nance (MR). Imaging MRI is superior to CT for evalua-
tion of tongue, perineural spread, skull base invasion and 
intracranial extension. Regarding lymphatic dissemina-
tion, defining extracapsular nodal extension is of prog-
nostic value.
-CT of chest preferably, or X-ray in early stages.
-Positron emission tomography-CT (PET-CT) is very use-
ful in diagnosis of node (N) and metastases (M) and syn-
chronous primary tumors. It is recommended in patients 
with stage III–IV disease when definitive treatment is 
indicated or in those with equivocal findings on CT or 
MRI scan [3].
-Esophageal–gastric contrast study or esophagoscopy in 
case of dysphagia.
-Histological diagnosis is mandatory by primary tumor 
biopsy or fine needle aspiration (FNA) of lymph nodes 
(biopsy is always better than FNA). If a node biopsy is 
needed, complete nodal resection is preferable to prevent 
extracapsular metastatic spread [2].
Table 1  Strength of 
recommendation and quality of 
evidence score
*Studies reported as abstracts in congresses pending journal publication at the time of writing this guide
Category, grade Definition
Strength of recommendation
 A Good evidence to support a recommendation for use
 B Moderate evidence to support a recommendation for use
 C Poor evidence to support a recommendation
 D Moderate evidence to support a recommendation against use
 E Good evidence to support a recommendation against use
Quality of evidence
 I Evidence from ≥ 1 properly randomized, controlled trial
 II Evidence from ≥ 1 well-designed clinical trial, without rand-
omization; from cohort or case controlled analytic studies 
(preferably from > 1 centr*e); from multiple time series; or 
from dramatic results from uncontrolled experiments
 III Evidence from opinions of respected authorities, based 
on clinical experience, descriptive studies, or reports of 
experts committees
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-Functionalism evaluation: chewing, swallowing, phona-
tion, breathing (stability of the airway mast be assessed), 
odontology and nutritional status.
-Special evaluations if needed: psychological and social 
situation, cessation of smoking or alcohol dependence.
Accurate staging is crucial for coordinating and tailoring 
therapy to each individual patient. The 8th edition of TNM 
classisfication was implemented from January, 2018: [4]
-The most important introduction is an independent clas-
sification for p16-positive oropharyngeal tumors: in the T 
category, T4a and T4b were pooled as T4, and N category 
was reclassified. As a consequence, there is a downstag-
ing.
-T category (T1–T3) of lip and oral cavity includes the 
extent of depth invasion.
-N3 category for non-HPV related tumors has been sub-
divided into N3a and N3b according to extranodal exten-
sion (in N1 and N2 categories lack of extranodal exten-
sion is specified).
-Perineural invasion or deep invasion is included within 
squamous cell carcinomas of the skin.
Early disease (clinical stage I–II) treatment
Surgery, 3D conformal radiotherapy (RT) and brachytherapy 
provide similar locoregional control and survival outcomes, 
but they have not been compared in randomized trials [2]. 
A multidisciplinary team should choose according to the 
characteristics and wishes of the patient and the potential 
functional outcomes, a single modality to avoid morbidity.
Transoral resection is preferred over RT in oral cavity 
because of the decreased long-term morbidity (II, B) [5]. 
In oropharyngeal carcinoma, minimally invasive transoral 
surgery such as robot (TORS) or laser (TLM), in selected 
patients, should be prioritized over open surgery (II, B) [6]. 
Alternative RT seems to have less tendency to long-term 
dysphagia (II, B) [7].
In both locations, cervical lymph nodes should be treated 
with prophylactic radiation or elective neck dissection (bilat-
erally in tumors that arise in or near the midline and guided 
by location and depth in oral carcinoma) (II, B) [8].
Recent data recommend treatment based on sentinel 
node biopsy for oral cavity and oropharynx tumors (T1–2 
N0), since it obtains the same neck-relapse-free survival at 
2 years than the neck dissection, with less morbidity during 
first year post-surgery (I, A) [9]. When cervical dissection 
is indicated, we would recommend elective neck dissec-
tion over therapeutic neck dissection due to similar efficacy 
with  less morbidity associated (I,A) [10]. In the choice of 
treatment for hypopharyx and larynx carcinomas, laryngeal 
functional results will be considered in addition to survival. 
Conservative laryngeal surgery (TLM or supraglottic or 
supracricoid laryngectomy) will be priorized over open 
surgery, and considerer RT treatment in case of requiring 
extensive surgical resection [11, 12]. Elective treatment of 
the neck in hypopahrynx and supraglottic cancer is recom-
mended (II, B), but not in glottic neoplasm (III, C).
If the pathological staging is superior to the clinical stag-
ing or there are poor prognosis factors, complementary treat-
ments should be used (I, A) including the re-resection.
Locally advanced disease (clinical stages III, 
IVA, IVB) treatment
In all cases there must be a multidisciplinary assessment to 
decide the best combined treatment option for each patient 
either based on surgery or RT as the key treatment (I-A) 
Given its special interest, we will introduce a special sec-
tion for larynx preservation and HPV-related oropharyngeal 
cancer treatments.
Surgery‑based treatment
There is no universally accepted definition of unresectabil-
ity in SCCHN, but some anatomical criteria are considered 
unequivocal and classified as T4b tumors (involvement of 
skull base, cervical vertebrae, prevertebral muscles, brachial 
plexus, mediastinal spread, involvement of nasopharynx, 
fixed tumor to collarbone, vascular encasement) [13].
Multidisciplinary Tumor Boards can exclude patients for 
surgery: few chances of achieving adequate margins, unac-
ceptable functional and/or esthetic sequelae, little expecta-
tion of cure or due to patients’ comorbidities.
For patients with T3-4aN0 tumors an ipsilateral or bilat-
eral neck dissection is an option (except oral cavity where 
it is mandatory). When neck nodes are palpable, all nodal 
levels should be dissected [14].
Adjuvant treatment
-Preferred Radiation technique: Intensity Modulated 
Radiotherapy (IMRT) 60–66 Gy (I-A) [15].
-Radiotherapy alone: it could be considered when there 
are multiple positive neck nodes (without extranodal 
extension), perineural invasion, vascular invasion, lym-
phatic invasion, pT3 or pT4 primary, oral cavity or oro-
pharyngeal primary cancers with positive level IV or V 
nodes (I-A).
-Concurrent chemorradiotherapy (CCRT): three-weekly 
intravenous cisplatin 100 mg/m2 at days 1, 22, 43) in 
high-risk pathological features: extracapsular lymph node 
extension and/or affected margins (I-A) [16, 17]. Weekly 
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40 mg/m2 cisplatin can be non-inferior alternative with 
better safety profile (IB) [18].
Specific recommendations in special circumstances
-Oral cavity: in clinically node-negative cases, elective 
ipsilateral node dissection is recommended more than 
watchful waiting approach (I-A) [10].
-Unfit patients not candidate for platinum: consider 
administration of RT alone (I-A). There is no evidence 
for using agents such as cetuximab or carboplatin in the 
adjuvant setting [14].
Radiotherapy‑based treatment
CCRT is preferred for patients that are not candidates for or 
refuse radical surgery (IA) (Fig. 1).
– RT technique: IMRT is preferred (IA) [19]: with similar 
overall survival compared with conventional RT, it has 
shown reduction in xerostomia (IA) [15] and probably 
shorter duration of feeding tube placement (V) [20].
– RT dose: for primary tumor and involved lymph nodes a 
total of 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/frac-
tion) (IA) For elective irradiation of risk sites 44–50 Gy 
(2.0 Gy/fraction) is proposed (IA) [21–23].
– Chemotherapy regimen: The standard schedule is cispl-
atin (100 mg/m2 days 1, 22, 43) (IA). Weekly cisplatin 
and other drug combinations have not demonstrated to 
be equivalent to high-dose cisplatin (IIB) [24, 25]. Con-
comitant cetuximab is an alternative treatment (400 mg/
m2 at initial dose day -8 followed by 250 mg/m2 weekly 
concurrent) for patients with some contraindication for 
cisplatin such as neuropathy, nephropathy, heart disease 
and hearing loss (IA) [24].
Sequential therapy with induction chemotherapy (ICT) 
followed by CCRT or RT alone is an option for locally 
advanced tumors (IIB) (Fig. 1). Factors such as patients’ 
comorbidities, high tumor volume and rapid tumor growth 
will influence its indication by a multidisciplinary team. 
ICT has not demonstrated improvement in overall com-
pared with concurrent CRT but increase the response rate. 
Its limitation is the potential toxicity that could compro-
mise the posterior CRT compliance.
The most recommended induction regimen is TPF 
schedule (three-weekly Cisplatin 75 mg/m2, Docetaxel 
75 mg/m2, 5-Fluorouracil 750 mg/m2/d continue infusion 
96 h) (IA) [25].
After ICT, there is no consensus for locoregional treat-
ment (RT, chemoradiotherapy or RT plus cetuximab) 
(IIB). Decision should be made according to the response 
and tolerance to previous ICT [26]. Salvage neck dissec-
tion should be considered in patients with residual lymph 
node disease and a complete response in the primary 
tumor.
Fig. 1  Treatment options in locally advanced SCCHN
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Organ preservation (larynx and hypopharynx)
All patients should have a multidisciplinary evaluation 
regarding their suitably for a larynx-preservation approach. 
Organ-preservation surgery, CRT and ICT, all with further 
surgery reserved for salvage, offer the potential for larynx 
preservation without compromising overall survival. Selec-
tion of a treatment option will depend on patient factors, 
including age, comorbidities, preferences, socioeconomic 
factors, local expertise and the availability of appropriate 
support and rehabilitation services.
For selected patients with extensive T3 or large T4a 
lesions and/or poor pretreatment laryngeal function, bet-
ter survival rates and quality of life may be achieved with 
total laryngectomy rather than with organ-preservation 
approaches and may be the preferred approach (IA).
CCRT offers a significantly higher chance of larynx pres-
ervation than RT alone or ICT followed by RT alone (IA). 
The best available evidence supports the use of high-dose 
cisplatin as the drug of choice in this setting [27].
There is insufficient evidence to indicate that survival or 
larynx-preservation outcomes are improved by the addition 
of ICT before concurrent treatment [28]. However, in the set-
ting of operable cancer with the goal of larynx preservation, 
response to ICT serves as a surrogate predictive biomarker 
for successful organ preservation with subsequent RT plus 
cisplatin.
Three options could be considered: Three options could 
be considered: 
1.Surgical resection (total versus partial laryngec-
tomy + neck dissection) followed by RT (IA)
•Specially in T4a (IA).
•For the most part of subglottic tumors (IA).
Non-surgical organ preservation alternatives are 
showed in Fig. 2:
2.CRT with three-weekly cisplatin is recommended if 
patient refuses surgery (IA). If cisplatin cannot be admin-
istered, consider cetuximab concurrent to RT (IA).
3.ICT with TPF schedule:
•If complete response of the primary tumors (without 
lymph node progression) → RT(IA).
•If partial response (50% reduction of primary tumor 
without lymph nose progression) → RT (IA) or con-
comitant RT (with cisplatin or cetuximab) [29] (IIB).
•If stable disease (primary tumor) or progres-
sion → total laryngectomy (including neck dissec-
tion) followed by RT (IA) or CRT (IIB) based on his-
topathological results.
HPV‑related oropharyngeal cancer: a new 
biological and clinical entity
HPV status has widely been described as an independ-
ent predictor of improved outcomes in squamous cell 
oropharyngeal cancer (OPSCC) patients, proving a 58% 
reduction in the risk of death for patients with HPV-related 
OPC as compared HPV-negative tumors [30].
Fig. 2  Organ preservation: Larynx/hypopharynx tumors candidate to total laryngectomy
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Diagnosis and staging
p16INK4a over-expression is a surrogate marker of HPV 
involvement and it is the most widely implemented 
technique in the clinical setting. Nevertheless, a recent 
study highly recommends confirming HPV relatedness in 
p16-positive patients with an HPV specific biomarker such 
us HPV DNA (IIA) [31]. Double testing for oropharyngeal 
HPV-related patients is especially important in our geo-
graphical area [31, 32].
Importantly, HPV-related oropharyngeal cancer 
patients’ staging should be done following AJCC TNM 
8th edition, whereas clinical decision-making should fol-
low AJCC TNM 7th edition.
Early disease
Minimally invasive surgery (TORS or TLM) or IMRT mono-
therapies are both validate techniques for early stages (IA). 
Importantly patient characteristics and wishes, functional out-
comes and expertise of the treating team should be considered.
Locally advanced (LA) disease
The good prognosis has led the scientific community to 
develop de-escalation clinical trials for LA HPV-related 
OPSCC patients [33]. Two phase III de-escalation clini-
cal trials have maintained cisplatin (100 mg/m2 every 
3 weeks) in combination with RT (70 Gy in 35 fractions) 
as the standard of care (IA) [34, 35]. Deintensification 
protocols should be undertaken only within the context 
of clinical trials.
Recurrent or metastatic (R/M) disease
Surgery or re-irradiation should always be assessed by the 
multidisciplinary team for oligometastasic patients. If a radi-
cal approach is not possible, the clinical management of R/M 
HPV-related oropharyngeal patients does not differ from 
R/M HPV-negative HNSCC, except for patients included 
on specific clinical trials (IA).
R/M disease treatment
The multidisciplinary team will assess the benefit of 
salvage surgery or re-irradiation. In the presence of 
oligometastatic disease, treatment with curative intent 
should also be discussed. Systemic treatment will be con-
sidered in all other patients. All subjects should be recom-
mended including in clinical trials if available.
First‑line treatment
Decisions will be made based on Eastern Cooperative 
Oncology Group (ECOG) performance status (PS) comor-
bidities, symptom burden and PD-L1 expression (in archi-
val or newly tumor samples and characterized by the com-
bined positive score (CPS)).
1. Chemotherapy-naïve patients or patients with progres-
sive disease more than 6 months after locoregional treat-
ment with cisplatin (Fig. 3):
(a) Pembrolizumab alone is preferred in patients with 
PS 0/1, CPS ≥ 20 and low symptom load (IA) 
[36].
(b) The combination of Pembrolizumab plus chem-
otherapy might be preferred for patients whose 
symptom burden indicates a greater importance 
of objective response. (IA) [36].
(c) In patients with CPS 1–19 the combination of 
Pembrolizumab plus chemotherapy (platinum plus 
5 FU) is the treatment of choice too (IA) [37].
(d) If CPS < 1 or the patient cannot be treated with an 
immunotherapy protocol EXTREME (combina-
tion based on platinum plus 5-FU plus cetuximab) 
(IA) [38] or TPEX (combination based on cispl-
atin plus docetaxel plus cetuximab if there is any 
contraindication to 5-FU) only in PS 0/1 patients 
able to receive cisplatin (IIB) [39]* are the best 
option.
(e) Best supportive care is the treatment of choice 
in patients with PS 2. In these patients and those 
with comorbidities that could not receive plati-
num the combination ERBITAX (paclitaxel plus 
cetuximab) should be considered (IIB) [40].
(f) The treatment of choice for patients with PS 3/4 
is best supportive care.
2. Patients who have received chemotherapy at least 
200 mg/m2 of cisplatin for locoregional disease within 
6 months after last cisplatin dose should not receive cis-
platin or carboplatin. The first option will be Nivolumab 
(IA) [41] or Pembrolizumab in those patients with a 
tumor positive score (TPS) >/=50% (IIA) [42]. Accord-
ing to PS or symptom burden treatment with ERBITAX 
[40] could be an alternative (Fig. 3).
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Second and subsequent line treatment
With the paradigm switch at the frontline we can find new 
treatment settings:
1. After platinum-based therapy: immunotherapy with 
Nivolumab (IA) [41] Pembrolizumab in those patients 
with tumor positive score (TPS) PDL1 ≥ 50% (IIA) [42]
2. After pembrolizumab alone: combination EXTREME is 
preferred or ERBITAX according to PS (IIIC).
3. After pembrolizumab plus platinum and 5-FU: combina-
tion ERBITAX (IIIC).
4. Other cases: considered according to PS single-agent 
therapy with taxanes (docetaxel, paclitaxel) or anti-
metabolite drugs (capecitabine or 5-FU, methotrexate) 
(IIC). Second and subsequent-line trials tested different 
                                               
o LA. Locoregionally advanced
o ECOG: Eastern Cooperative Oncology Group
o CPS: Combined Positive Score
o BSC: Best Supportive Care
o CT: Chemotherapy
o ERBITAX: combination of paclitatel and cetuximab
o EXTREME: combination of platinum, 5-Fluorouracil and cetuximab
o TPEX: combination of cisplatin, docetaxel and cetuximab
2nd line 
o EXTREME/TPEX  
o ERBITAX 
o Nivolumab 




Progression > 6 months LA* disease
Recurrent/metastatic disease 
Patient Fit (ECOG 0-1) 
o CPS ≥ 20 
Pembrolizumab or 
Pembrolizumab + CT 
o CPS 1-19
Pembrolizumab or 
Pembrolizumab + CT 
o CPS < 1
EXTREME/TPEX 




Progression < 6 







Fig. 3  Recurrent/metastatic disease treatment. All patients should be 
recommended including in clinical trials if available. LA Locoregion-
ally advanced, ECOG Eastern Cooperative Oncology Group, CPS 
combined positive score, BSC best supportive care, CT chemother-
apy, ERBITAX combination of paclitatel and cetuximab, EXTREME 
combination of platinum, 5-Fluorouracil and cetuximab, TPEX com-
bination of cisplatin, docetaxel and cetuximab
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drugs with small sample sizes and patient heterogeneity 
which makes the evaluation of the relative efficacy of 
each drug challenging. There is no evidence of higher 
efficacy among the different drugs in the meta-analyses 
performed [43].
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